Evidence map›Paper›PMID 41286502›Full record

ArticleCommunications biology2025

Noncanonical amino acid-aided synthesis of anti-PD-L1 bispecific nanobody for colon cancer immunotherapy.

Xinyu Hu, Ling Jiang, Haibin Yuan, Wanyi Chen, Yufei Guo, Mengxue Gao, Yijia Song, Zichen Wang, Yuli Wang, Miao Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xinyu Hu *School of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.ORCID http://orcid.org/0009-0004-9451-0374
Ling Jiang *Institute of Bioengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, China.ORCID http://orcid.org/0000-0002-0391-6941
Haibin Yuan *School of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.
Wanyi ChenInstitute of Bioengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, China.
Yufei GuoSchool of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.
Mengxue GaoSchool of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.
Yijia SongSchool of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.
Zichen WangSchool of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.
Yuli WangSchool of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.
Miao ZhangSchool of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.
Ario de MarcoLaboratory for Environmental and Life Sciences, University of Nova Gorica, Nova Gorica, Slovenia.
He HuangSchool of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China. huang@tju.edu.cn.ORCID http://orcid.org/0000-0003-3008-4869
Guangbo KangSchool of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China. guangbo_kang@tju.edu.cn.ORCID http://orcid.org/0000-0001-5353-9788
Haoran YuInstitute of Bioengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, China. yuhaoran@zju.edu.cn.ORCID http://orcid.org/0000-0001-9012-4688

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22108245
6 · The paper itself

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality, and the incidence of early-onset colon cancer has been increasing globally in recent years. The development of immunotherapies for colon cancer is critical for providing new treatment strategies to combat drug resistance. Here, a bispecific nanobody against PD-L1 (BsNb-PD-L1) constructed using genetically encoded noncanonical amino acids (ncAAs) is reported. A computational protocol was developed to identify appropriate sites in the nanobody for incorporating p-acetylphenylalanine (pAcF). Variants of nanobodies PV2 and PV3 with pAcF incorporated were conjugated with linkers containing an aminooxy functionality to enable oxime ligation. The resulting PV2-S71 + PV3-N77 bispecific nanobody (BsNb-ncAA) exhibited higher thermostability and binding affinity compared to the nanobody monomers and the BsNb constructed by simply fusing two proteins. Moreover, in an in vitro phagocytosis model, the BsNb-ncAA exhibited improved capability to inhibit immune evasion and showed stronger biological activity compared to the fusion protein PV2-PV3. Furthermore, the BsNb-ncAA resulted in a marked increase in the number of CD8

Indexed as

Amino AcidsAntibodies, BispecificB7-H1 AntigenColonic NeoplasmsImmunotherapySingle-Domain AntibodiesAnimalsCell Line, TumorFemaleHumansMiceAmino AcidsAntibodies, BispecificB7-H1 AntigenCD274 protein, humanSingle-Domain Antibodies

Identifiers

PMID41286502
PMCPMC12749753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.